Atypical BRAF and NRAS Mutations in Mucosal Melanoma.

Atypical BRAF and NRAS Mutations in Mucosal Melanoma.

Publication date: Aug 08, 2019

Primary mucosal melanomas represent a minority of melanomas, but have a significantly worse prognosis than cutaneous melanomas. A better characterization of the molecular pathogenesis of this melanoma subtype could help us understand the risk factors associated with the development of mucosal melanomas and highlight therapeutic targets. Because the Mitogen-Activated Protein Kinase (MAPK) pathway plays such a significant role in melanoma development, we explore v-raf murine sarcoma viral oncogene homolog B (BRAF) and neuroblastoma RAS viral oncogene homolog (NRAS) mutations in mucosal melanoma and compare them to the mutation profiles in cutaneous melanoma and other tumors with BRAF and NRAS mutations. We show that in addition to being less frequent, BRAF and NRAS mutations are different in mucosal melanoma compared to cutaneous melanomas. Strikingly, the BRAF and NRAS mutation profiles in mucosal melanoma are closer to those found in cancers such as lung cancer, suggesting that mutations in mucosal melanoma could be linked to some genotoxic agents that remain to be identified. We also show that the atypical BRAF and NRAS mutations found in mucosal melanomas have particular effects on protein activities, which could be essential for the transformation of mucosal melanocytes.

Dumaz, N., Jouenne, F., Delyon, J., Mourah, S., Bensussan, A., and Lebb’e, C. Atypical BRAF and NRAS Mutations in Mucosal Melanoma. 23713. 2019 Cancers (Basel) (11):8.

Concepts Keywords
Basel Significant melanoma
BRAF Raf murine sarcoma
Genotoxic Cancers lung cancer
Homolog Minority melanomas
Lung Cancer Melanoma
Melanocytes Medicine
Melanoma Neoplasms
Melanomas Oncogenes
Mitogen Cancer
Murine RTT
Mutation BRAF
Neuroblastoma NRAS
Oncogene Mucosal melanoma
Pathogenesis Ras GTPase
Prognosis
Raf
RAS
Sarcoma
Viral

Semantics

Type Source Name
disease DOID lung cancer
disease MESH lung cancer
disease MESH tumors
disease DOID cutaneous melanoma
drug DRUGBANK Rasagiline
disease DOID neuroblastoma
disease MESH neuroblastoma
disease DOID sarcoma
disease MESH sarcoma
gene UNIPROT RAF1
gene UNIPROT ZHX2
disease MESH development
disease MESH risk factors
pathway BSID Melanoma
disease DOID melanoma
drug DRUGBANK Tropicamide
disease MESH melanomas
disease DOID Mucosal Melanoma
gene UNIPROT NRAS
gene UNIPROT BRAF

Similar

Original Article

Leave a Comment

Your email address will not be published. Required fields are marked *